Diltiazem Infusion Dosing Protocol
For acute rate control in atrial fibrillation/flutter or supraventricular tachycardia, administer diltiazem as an initial bolus of 0.25 mg/kg (15-20 mg for average adult) IV over 2 minutes, followed by a maintenance infusion starting at 5-10 mg/h, titrated up to a maximum of 15 mg/h based on heart rate response.
Loading Dose
- Initial bolus: 0.25 mg/kg (typically 15-20 mg) IV over 2 minutes 1, 2, 3
- Second bolus (if needed): 0.35 mg/kg (typically 20-25 mg) IV administered 15 minutes after the first dose if inadequate response 1, 3
- Patients with low body weight should be dosed on a mg/kg basis rather than using fixed doses 3
Maintenance Infusion
Start the continuous infusion immediately after achieving initial heart rate control with the bolus dose:
- Initial rate: 10 mg/h (some patients may respond to 5 mg/h) 1, 3
- Titration: Increase in 5 mg/h increments as needed 3
- Maximum rate: 15 mg/h 1, 2, 3
- Maximum duration: 24 hours 1, 3
The 2016 ACC/AHA/HRS guidelines specify the maintenance infusion range as 5-10 mg/h, up to 15 mg/h 2, while the 2010 AHA ACLS guidelines describe it as 5-15 mg/h 1. The FDA label confirms that infusion rates exceeding 15 mg/h and durations beyond 24 hours have not been adequately studied and are not recommended 3.
Critical Safety Parameters
Hold or reduce the infusion if:
- Systolic blood pressure drops below 100 mm Hg
- Heart rate falls below 50-60 bpm
- Development of second- or third-degree AV block
- Signs of heart failure decompensation
Absolute Contraindications
Do not use diltiazem in patients with:
- Pre-excited atrial fibrillation/flutter (WPW syndrome) - may accelerate ventricular response 1, 2, 1
- Decompensated systolic heart failure or LV dysfunction 2
- AV block greater than first degree (without pacemaker) 2
- Hypotension (SBP <100 mm Hg) 2
- Cardiogenic shock 2
- Wide-complex tachycardias of uncertain origin 1
Practical Considerations
Diltiazem demonstrates dose-dependent, non-linear pharmacokinetics 3, meaning the relationship between dose and effect is not proportional. The 2024 AF guidelines confirm diltiazem as a first-line agent for rate control, with the same dosing parameters 4.
Common adverse effects include hypotension (most frequent), bradycardia, and potential precipitation of heart failure in patients with pre-existing ventricular dysfunction 1, 2. Recent evidence from 2024 suggests that in some ED populations, diltiazem infusions after bolus dosing may be associated with less effective rate control compared to bolus alone 5, though this requires clinical judgment based on individual patient response.
Drug interactions: Diltiazem is a CYP3A4 substrate and moderate inhibitor 2, requiring caution with medications metabolized through this pathway. Avoid combining with other AV nodal blocking agents (beta-blockers, digoxin, verapamil) due to risk of profound bradycardia 1.
Transition to oral therapy: When converting from IV to oral diltiazem, administer the first oral dose (typically diltiazem CD 180-360 mg) and discontinue the infusion 4 hours later 6. Approximately 77% of patients maintain rate control during this transition.
Hepatic and renal dysfunction: Use with caution and consider dose reduction, as diltiazem undergoes hepatic metabolism 2.